drugset / Trial / NCT05595993
Hypersensitivity to Phosphodiesterase 3 Inhibition in Post-Traumatic Headache
RandomizedCrossoverQuadruple-blindBasic science
Summary
To investigate whether cilostazol (phosphodiesterase 3 inhibitor) induces headache with migraine-like features in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).
Timeline
- Start
- 2022-10-25
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cilostazol | Small molecule | 200 mg | Oral |
Indications
No indication recorded.